Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study

Yoo, Jeong‐Ju; Yoo, Yang Jae; Moon, Woo Ram; Jeong, Soung Won; Park, Ha Na; Park, Min-Gyu; Jang, Jae Young; Park, Suyeon; Kim, Seung Up; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Kim, Sang Gyune; Kim, Young Seok; Kim, Ji Hoon; Yeon, Jong Eun; Byun, Kwan Soo

doi:10.3904/kjim.2018.309

Cited by 4 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, liver USG is an accurate, reliable tool to detect moderate to severe fatty liver, with sensitivity and specificity of 84.8% and 93.6%, respectively [ 19 ]. Also, the CAP value significantly correlates with the USG-based steatosis grading and the median CAP value for each USG-based steatosis grade shows a positive dose-response relationship [ 20 ]. This observation is in line with our study also, which showed CAP steatosis grading correlated positively and significantly with the USG grading of fatty liver (p<0.001).…”

Section: Discussionmentioning

confidence: 99%

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Shrestha¹,

Kc²,

Thapa³

et al. 2021

Cureus

View full text Add to dashboard Cite

BackgroundAssessment of nonalcoholic fatty liver disease (NAFLD) includes estimation of liver fat (steatosis).Controlled attenuation parameter (CAP) value obtained by FibroScan ® (Echosens, Paris, France) is an alternative to liver biopsy for diagnosing and estimating steatosis (S). This study aimed to estimate the liver fat by CAP in NAFLD patients. MethodsAn observational cross-sectional study was conducted at the Liver Unit of Bir Hospital, from January 2021 to May 2021 after ethical clearance from the Institutional Review Board of the National Academy of Medical Sciences. A convenient sampling method was used. Data were analyzed with descriptive and inferential statistics involving bivariate and multivariate analysis. ResultsA total of 127 NAFLD patients were enrolled. The mean (±SD) CAP value was 271.53 (±50.69) dB/m. Total cholesterol, triglyceride, and body mass index (BMI) correlated positively (p<0.05) while systolic blood pressure correlated negatively with CAP value (p=0.031). On multivariate analysis, patients with BMI ≥25 kg/m 2 were found 3.7 times more likely to have CAP ≥291 dB/m (S3, severe steatosis) than those with BMI <25 kg/m 2 (p=0.048, 95% CI 1.01, 13.50). The mean (±SD) CAP values were 276.19 (±49.93) and 246.60 (±48.50) dB/m among those with BMI ≥25 kg/m 2 and <25 kg/m 2 , respectively (p=0.016, using independent ttest). CAP steatosis grading correlated positively with both the ultrasound grading (p<0.001) and fibrosis grading by liver stiffness measurement (p=0.004). ConclusionIn this observational cross-sectional study of NAFLD patients, the mean (±SD) CAP value was 271.53 (±50.69) dB/m, which corresponds to moderate steatosis (S2). Obese NAFLD patients with ≥25 kg/m 2 were 3.7 times more likely to have severe steatosis (S3) than nonobese NAFLD patients with BMI <25 kg/m 2 .

show abstract

Section: Discussionmentioning

confidence: 99%

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Shrestha¹,

Kc²,

Thapa³

et al. 2021

Cureus

View full text Add to dashboard Cite

show abstract

Metabolic-associated fatty liver voxel-based quantification on CT images using a contrast adapted automatic tool

Martín-Saladich,

Pericàs,

Ciudin

et al. 2024

Medical Image Analysis

View full text Add to dashboard Cite

The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A

Neshatbini Tehrani,

Hatami,

Helli

et al. 2024

Sci Rep

View full text Add to dashboard Cite

A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST) and controlled attenuation parameter (CAP) score were significantly decreased only in the soy isoflavone group (P < 0.05). A significant decline in the gamma glutamyl transferase (GGT) level was observed only in the placebo group (P = 0.017). A significant increase in the serum level of fetuin A was shown in both groups at the end of the trial with a significantly greater increment in the soy isoflavone group compared to the placebo group (P < 0.05). The changes in the serum level of FGF-21 were not significant in any of the two groups. Steatosis grade significantly improved only in the soy isoflavone group (P = 0.045). There was no significant change in the fibrosis grade in the groups. Soy isoflavone intake led to a decrease in ALT, AST, CAP score, steatosis grade and an increase in the level of fetuin A. However, no significant changes were observed in the fibrosis grade and serum levels of GGT and FGF-21.

show abstract

Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study

Cited by 4 publications

References 33 publications

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease

Metabolic-associated fatty liver voxel-based quantification on CT images using a contrast adapted automatic tool

The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A

Contact Info

Product

Resources

About